about
CTLA-4 blockade: therapeutic potential in cancer treatmentsNonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected childrenPCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabCurrent stage in inflammatory bowel disease: What is next?New developments in atherosclerosis: clinical potential of PCSK9 inhibitionThe clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaClinical development methodology for infusion-related reactions with monoclonal antibodiesComparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studiesLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsCustomizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applicationsNew antiresorptive therapies for postmenopausal osteoporosisBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchTargeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging GliomasEngineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of BiotherapeuticsKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentHerpesvirus reactivation and socioeconomic position: a community-based studyIdentification of key processes that control tumor necrosis factor availability in a tuberculosis granulomaCharacterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activityTargeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationOzanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsiesTargeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog FludarabineLong-term treatment of osteoporosis: safety and efficacy appraisal of denosumabMolecular Imaging of Pancreatic Cancer with Antibodies.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosisImmunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopeniaPharmacokinetics of intravenous immunoglobulin: a systematic review.Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody.FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptorPopulation Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma.Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenograftsIdentification of lung cancer with high sensitivity and specificity by blood testing.Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration.Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
P2860
Q24622666-C627F5C0-7C89-471F-B642-9750D20553FAQ24679084-0A317B81-7011-4FA5-857B-5AFDC4BB5B28Q26747776-87D53EB2-2A18-4B0F-A2BC-66DDFBD205FAQ26777429-4C6364EE-4F3D-48AA-8A52-1563644CE485Q26783407-44127263-0F8C-47C7-8562-D6BEBBCFDEEEQ26783425-F2F779A9-E5B6-41ED-B7C3-ADDAC5393118Q26798184-FD85B639-71C7-43BD-8E3A-26B27E7AF3C3Q26830923-7E45BB98-6967-4443-BD00-BA38D97F84E2Q26849243-ECA62F48-D207-4603-82F6-0C6B93D9F568Q26864041-AA2463D8-E89E-42EF-B49A-44A638F7C8DFQ27014775-1B8FDC96-91BE-4A58-992D-E8A0CCB4A515Q27021268-66DD14BF-D29A-4E2D-BB76-65DF114961B8Q27024682-0B5753CE-1151-4894-9200-FAA868693BFEQ27335251-3033313A-A4D1-40EC-B12A-B63D9B9F0E91Q27677555-D935CA28-2B18-4DDA-A37E-73393AA971A6Q28082880-C73E0FC7-BAE4-4BD1-AEF4-EF4C5F014CC2Q28385076-37264F3D-0300-4B2F-B6A7-5D17C9BBCAECQ28473855-B7DC1099-11B7-4D44-91B5-CD6E74AF8144Q28475305-47F02B59-9F2B-4951-B2AF-306A02012B07Q28476825-A96F01B6-6B4B-4EC9-B716-B5DB89706838Q28543591-07FDE725-2D26-4185-A1D3-287ECBCEA619Q28550176-30492FE5-CBE6-4495-81D5-CD0C7F86B628Q28727655-8E9AFFA2-6C1F-420B-A84E-0E1BA07C247BQ30393523-A81313E4-4C72-486C-BE6D-8D9727F680BAQ30412650-34227F16-8C32-4217-9524-6BAD1715B2E4Q30489162-5FF4A33E-368D-4D1F-BAD9-5B018C5F08ECQ30716340-CA923D86-3451-4FB4-AF43-D85C5FD9C3F5Q30930928-B6208899-CCB5-4CC7-B2C1-FEC053092C38Q31012029-B9887550-7C4B-44BC-A297-33C9B287E578Q33370766-D46BA2F0-1B52-4297-B022-B295A115BDDCQ33371277-00810058-D77C-4E98-A6FA-0857680F146BQ33399704-AC5511CF-A14C-40D2-8A13-B9F93258522CQ33405623-2552D95F-5BCF-41EA-8785-C85A0FAC1BE1Q33519532-5AD49D50-BBE5-46B2-8848-59C3A5C60DD5Q33573587-6D753B67-64D0-48DB-ABD3-FEEE5EE57596Q33581536-75773600-BF7C-43D8-B2D6-E389D8C6F58EQ33688233-418D52B4-A458-4E28-A48E-E7E0CA307EDAQ33705551-7A208719-3BE2-46FA-ABDE-2647511F929DQ33728344-8C11A923-2BD2-4A80-BE37-A4E3BE3F74D1Q33770199-92098683-4425-4304-8F47-0420139A7871
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antibody pharmacokinetics and pharmacodynamics.
@ast
Antibody pharmacokinetics and pharmacodynamics.
@en
type
label
Antibody pharmacokinetics and pharmacodynamics.
@ast
Antibody pharmacokinetics and pharmacodynamics.
@en
prefLabel
Antibody pharmacokinetics and pharmacodynamics.
@ast
Antibody pharmacokinetics and pharmacodynamics.
@en
P2093
P356
P1476
Antibody pharmacokinetics and pharmacodynamics.
@en
P2093
Evelyn D Lobo
Joseph P Balthasar
Ryan J Hansen
P304
P356
10.1002/JPS.20178
P407
P577
2004-11-01T00:00:00Z